Metabolic monitoring in psychotic disorders

Introduction - The Metabolic Toll

• Second-generation antipsychotics (SGAs), while effective for psychosis, frequently induce metabolic syndrome, increasing cardiovascular risk.
• Mechanism: Primarily linked to potent antagonism of histamine H1 and serotonin 5-HT2C receptors, which drives appetite and weight gain.
• Core Features:
  • Weight gain (often >7% baseline)
  • Hyperglycemia / Type 2 Diabetes
  • Dyslipidemia (↑ Triglycerides, ↓ HDL)
  • Hypertension

⭐ Clozapine and olanzapine carry the highest metabolic risk; aripiprazole, lurasidone, and ziprasidone are among the lowest.

Screening Protocol - Check-Up Checklist

• All patients starting antipsychotics require baseline and ongoing metabolic screening.
• High-risk agents (e.g., Clozapine, Olanzapine) demand more frequent checks.
• Key parameters include: Body Mass Index (BMI), blood pressure, fasting glucose/HbA1c, and a fasting lipid panel.

⭐ The American Diabetes Association (ADA) recommends checking personal/family history, weight, BMI, blood pressure, fasting glucose, and lipids at baseline before or at the time of starting an antipsychotic.

Risk Stratification - The Usual Suspects

• High Metabolic Risk (↑↑↑ Weight Gain, Dyslipidemia, Hyperglycemia)

  • Clozapine
  • Olanzapine
  • 📌 Mnemonic: "Old Clothes" (Olanzapine, Clozapine) are riskiest for the waistline.

• Moderate Metabolic Risk

  • Risperidone
  • Paliperidone
  • Quetiapine
  • Iloperidone

• Low / Neutral Metabolic Risk (Lower Risk Profile)

  • Aripiprazole
  • Brexpiprazole
  • Ziprasidone
  • Lurasidone
  • Haloperidol (First-Gen)

⭐ Exam Favorite: Olanzapine and Clozapine consistently show the highest risk for significant weight gain and development of metabolic syndrome, necessitating the most stringent monitoring.

Management - The Damage Control Plan

• Tier 1: Lifestyle Intervention
  • Dietary counseling & structured exercise (≥150 min/week).
  • Behavioral weight management programs.
• Tier 2: Pharmacotherapy
  • Metformin for impaired glucose tolerance or T2DM.
  • Statins for dyslipidemia based on ASCVD risk.
• Tier 3: Antipsychotic Adjustment
  • Switch to a lower metabolic risk agent (e.g., aripiprazole, ziprasidone, lurasidone).
  • Avoid agents with high metabolic risk (e.g., olanzapine, clozapine).

⭐ High-Yield: Metformin can be initiated prophylactically along with a second-generation antipsychotic (especially olanzapine) to mitigate weight gain and insulin resistance, particularly in antipsychotic-naïve patients.

High‑Yield Points - ⚡ Biggest Takeaways

• Second-generation antipsychotics (SGAs), especially clozapine and olanzapine, carry the highest risk for metabolic syndrome.
• Lower-risk agents include aripiprazole, ziprasidone, and lurasidone.
• Regular monitoring includes BMI, blood pressure, fasting glucose or HbA1c, and a fasting lipid panel.
• Obtain baseline measurements before starting an SGA and monitor periodically, typically at 3 months and then annually.
• Management involves lifestyle modification, switching to a lower-risk SGA, or adding metformin.